Stay updated on Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial
Sign up to get notified when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.

Latest updates to the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page
- Check5 days agoChange DetectedA banner was added announcing an NIH website transition and updates about terminology for artificial intelligence. The study record remains unavailable behind a 403 error.SummaryDifference1%

- Check12 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check19 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1; the study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check33 days agoChange DetectedA 403 Forbidden error page was added, displaying a minimal header and a Home link, indicating restricted access to the study record rather than a content update.SummaryDifference0.5%

- Check40 days agoChange DetectedThe study page now renders a 403 Forbidden error, blocking access to the study record. As a result, the previous study content and documents listed on the page are no longer visible, replaced by the 403 page.SummaryDifference21%

- Check62 days agoChange DetectedRevision version updated to v3.6.6, replacing v3.6.5, indicating a minor site update without altering study data.SummaryDifference0.0%

Stay in the know with updates to Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.